8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Generate Biomedicines shares are trading lower after the company reported mixed Q2 financial results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 2:16 PM
- Checked
- Aug 6, 2026, 2:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of $(1.94) per share
Read original at benzingaCathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
Cathie Wood's Ark Invest expanded positions in three recently-IPO'd stocks on Monday: Space Exploration Technologies (SpaceX), Generate Biomedicines, and Bullish. SpaceX, trading 19% above its IPO price, joins the Nasdaq-100 on Tuesday which should drive passive buying. Generate Biomedicines, a clinical-stage biotech company with AI-driven drug discovery, is trading above its February IPO price. Bullish, a crypto exchange and media company, has plummeted 72% since going public due to crypto market weakness.
Read original at the-motley-fool